Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have been given a consensus rating of “Moderate Buy” by the seven analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $37.25.

Several research analysts have issued reports on the company. Weiss Ratings upgraded Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. Citigroup boosted their target price on shares of Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Zacks Research raised shares of Zai Lab from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, Wall Street Zen upgraded shares of Zai Lab from a “sell” rating to a “hold” rating in a research report on Saturday.

Zai Lab Trading Up 0.9%

ZLAB stock opened at $25.93 on Wednesday. Zai Lab has a 1-year low of $15.96 and a 1-year high of $34.72. The business’s 50 day moving average is $24.01 and its 200-day moving average is $21.08. The firm has a market cap of $2.95 billion, a P/E ratio of -15.16 and a beta of 0.83.

Zai Lab (NASDAQ:ZLAB) last posted its earnings results on Tuesday, June 30th. The company reported ($0.50) EPS for the quarter. The company had revenue of $106.31 million for the quarter. Zai Lab had a negative return on equity of 27.43% and a negative net margin of 41.86%. Sell-side analysts forecast that Zai Lab will post -2.17 EPS for the current year.

Insider Buying and Selling

In other Zai Lab news, Director William Lis sold 8,506 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $25.00, for a total transaction of $212,650.00. Following the sale, the director directly owned 41,931 shares of the company’s stock, valued at approximately $1,048,275. This represents a 16.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 9,385 shares of company stock valued at $235,145 in the last quarter. 4.88% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ZLAB. Nykredit A S acquired a new position in Zai Lab in the second quarter valued at approximately $79,000. Headlands Technologies LLC grew its holdings in Zai Lab by 142.0% during the 2nd quarter. Headlands Technologies LLC now owns 68,010 shares of the company’s stock worth $1,292,000 after acquiring an additional 39,901 shares during the period. Finally, Seven Fleet Capital Management LP grew its holdings in Zai Lab by 74.7% during the 2nd quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company’s stock worth $2,584,000 after acquiring an additional 58,158 shares during the period. 41.65% of the stock is owned by institutional investors and hedge funds.

About Zai Lab

Zai Lab Limited is a biopharmaceutical company focused on discovering, developing and commercializing medicines for significant unmet medical needs. The company’s research and development activities have centered on oncology, autoimmune and inflammatory diseases, infectious diseases, and neuroscience. Zai Lab operates through a combination of internally developed programs and collaborations with global pharmaceutical and biotechnology companies.

The company has built a commercial portfolio in Greater China that has included ZEJULA (niraparib), a PARP inhibitor used in certain ovarian cancer settings; QINLOCK (ripretinib), a treatment for gastrointestinal stromal tumors; and NUZYRA (omadacycline), an antibiotic for certain bacterial infections.